22 related articles for article (PubMed ID: 32892196)
1. PD-L1
Allbee AW; Gerson J; Yang G; Bagg A
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38199780
[TBL] [Abstract][Full Text] [Related]
2. Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.
Sivaram N; McLaughlin PA; Han HV; Petrenko O; Jiang YP; Ballou LM; Pham K; Liu C; van der Velden AW; Lin RZ
J Clin Invest; 2019 May; 129(8):3264-3276. PubMed ID: 31112530
[TBL] [Abstract][Full Text] [Related]
3. Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy.
Snow H; Mitchell C; Hendry S; McKinley M; Byrne D; Ngan S; Chander S; Chu J; Desai J; Bae S; Henderson M; Choong P; Gyorki D
J Surg Oncol; 2021 Jan; 123(1):117-126. PubMed ID: 33084061
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.
Traweek RS; Cope BM; Roland CL; Keung EZ; Nassif EF; Erstad DJ
Front Oncol; 2022; 12():1006959. PubMed ID: 36439412
[TBL] [Abstract][Full Text] [Related]
5. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
6. Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas.
Oike N; Kawashima H; Ogose A; Hatano H; Ariizumi T; Yamagishi T; Murayama Y; Umezu H; Imai C; Hayashi M; Endo N
Cancer Immunol Immunother; 2021 Dec; 70(12):3489-3499. PubMed ID: 33893830
[TBL] [Abstract][Full Text] [Related]
7. Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience.
Kim YN; Chung YS; Lee JH; Park E; Lee ST; Kim S; Lee JY
J Gynecol Oncol; 2023 Nov; 34(6):e70. PubMed ID: 37417298
[TBL] [Abstract][Full Text] [Related]
8. Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy.
Tural D; Akar E; Baytekin HF; Canoglu D; Yilmaz M; Tugcu V
J BUON; 2021; 26(5):2117-2125. PubMed ID: 34761625
[TBL] [Abstract][Full Text] [Related]
9. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Kim JH; Lee JS; Kim EJ; Park KH; Kim KH; Yi SY; Kim HS; Cho YJ; Shin KH; Ahn JB; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Noh SH; Rha SY; Kim HS
Oncotarget; 2016 Apr; 7(17):24549-58. PubMed ID: 27016421
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Jeon HM; Lee JS; Kim SH; Yun KH; Park KH; Jeon MK; Lee YH; Yoon HI; Suh JS; Hur H; Kim KS; Kim S; Kim SH; Kim HS
Oncology; 2020; 98(11):817-826. PubMed ID: 32892196
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
